Search Results 341-350 of 17365 for alopecia

1. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

   Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement;; Subjects with psoriasis ...

2. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgment are ...

3. DAREON™-9: A Study To Test How Well Different Doses Of BI 764532 Are Tolerated By People With Small Cell Lung Cancer When Taken Together With A Single Agent Chemotherapy - Mayo Clinic

   Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia ...

4. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Toxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia. ... alopecia) not requiring systemic treatment, or ...

5. Skin biopsy - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

6. CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin - Mayo Clinic

   Resolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity are allowed < grade 2; >1 week since palliative RT; Ability to ...

7. Publications - Donald W. Northfelt, M.D. - Mayo Clinic

   ... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D ...

8. A Study of the Combination of IMCgp100 with Durvalumab and/or Tremelimumab for Patients with Advanced Cutaneous Melanoma - Mayo Clinic

   ... alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ NCI CTCAE grade 3) due to prior cancer therapy; Chronic systemic corticosteroid use ...

9. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

   All ASCT-related toxicities must have recovered to ≤ Grade 1 (except for alopecia, fatigue and amenorrhea) prior to first randomization. Mucositis and ...

10. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

    * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.